Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma

British Journal of Cancer

Volumn 95, Issue 4, 2006, Pages 450-456

  Falk, S ^a   Anthoney, A ^b   Eatock, M ^c   Van Cutsem, E ^d   Chick, J ^e   Glen, H ^f   Valle, J W ^g   Drolet, D W ^h   Albert, D ^h   Ferry, D ⁱ   Ajani, J ^j  

^a BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^b United Kingdom   (United Kingdom)

^c BELFAST CITY HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e OSI Pharmaceuticals   (United Kingdom)

^f BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^g CHRISTIE HOSPITAL   (United Kingdom)

^h OSI PHARMACEUTICALS INC   (United States)

ⁱ NEW CROSS HOSPITAL   (United Kingdom)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Gastric GEJ cancer; OSI 7904L; Pharmacodynamics; Pharmacokinetics; Phase II

Indexed keywords

DEOXYURIDINE; HOMOCYSTEINE; OSI 7904L; STEROID; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CORRELATION ANALYSIS; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DYSGEUSIA; ENZYME INHIBITION; ERYTHEMA; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; GASTROINTESTINAL SYMPTOM; GENOTYPE; HAND FOOT SYNDROME; HUMAN; LETHARGY; LOWER ESOPHAGUS SPHINCTER; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; RASH; SKIN TOXICITY; STOMACH ADENOCARCINOMA; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; THRUSH; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; GLUTARATES; HUMANS; MALE; MIDDLE AGED; QUINAZOLINES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33747155842     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603267     Document Type: Article

References (34)

1. Ajani JA (2005) Evolving chemotherapy for advanced gastric cancer. Oncologist 10(S3): 44-58
2. Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P (2005) Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 23: 6957-6965
3. Beutel G, Glen H, Schöffski J, Chick J, Gill S, Cassidy J, Twelves C (2005) Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumours. Clin Cancer Res 11(15): 5487-5495
4. Desjardins J, Emerson D L, Colagiovanni D B, Abbott E, Brown EN, Drolet D (2004) Pharmacokinetics, safety, and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-{5- {1,2-Dihydro-3-methyl-1- oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric acid] in mice. J Pharmacol Exp Therap 309(3): 894-902
5. Ferlay J, Bray F, Pisani P, Parlen DM (2001) Globocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide VI.O. IARC Cancer Base No. 5 Lyon: IARC press
6. Fiskerstrand T, Refsum H, Kvalheim G, Ueland PM (1993) Homocysteine and other thiols in plasma and urine:automated determination and sample stability. Clin Chem 39(2): 263-271
7. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjödén PO, Haglund U, Svensson C, Enander L-K, Linné T, Sellsröm H, Heuman R (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8(2): 163-168
8. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K (1995) Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 20(3): 191-197
9. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics. CA Cancer J Clin 53: 5-26
10. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumours. Cancer Res 55: 1407-1412
11. Johnston PG, Benson III AB, Catalano P, Sambasiva Rao M, O'Dwyer PJ, Allegra CJ (2003) Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluruouracil in metastatic disease sites. JCO 21(5): 815-819
12. Kawakami K, Watanabe G (2003) Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res 63: 6004-6007
13. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Garcia Y, Li J, Leichman L (1995) Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumour response and overall survival. J Clin Oncol 14: 176-182
14. Mandola MV, Stoelmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ, Ladner RD (2003) A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 63: 2898-2904
15. Miyamoto S, Boku N, Ohtsu A, Yoshida S, Ochiai A, Okabe H, Fukushima M (2000) Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Int J Onc 17: 653-658
16. Moiseyenko VM, Ajani J, Tjulandin SA, Majlis A, Constenla M, Boni C, Anelli A, Yver AJ, Van Cutsem E (2005) Final results of a randomized controlled phase III trial (TAX325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC). Proc Am Soc Clin Onc 23(16S): Abtract 4002
17. Niyikiza C, Baker SD, Seitz DE, Walling JM, Nelson K, Rusthoven JJ, Stabler SP, Paoletti P, Calvert AH, Allen RH (2002) Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Therap 1: 545-552
18. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei D, Groshen S, Lenz HJ (2002) Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int J Colorectal Dis 17(1): 46-49
19. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108
20. Ricart AD, Berlin J, Syed S, Papadopoulos K, Drolet D, Quaratino-Baker C, Horan J, Chick J, Vermeulen W, Tolcher AW, Rowinsky EK, Rothenburg M (2005) Final results of a phase I and pharmacokinetic study of OSI-7904L in combination with cisplatin in patients with advanced solid tumours. NCI-AACR-EORTC, 97 [Abstract A166]
21. Ross P, Nicolson M, Cunningham DP, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A (2002) Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20: 1996-2004
22. Sarbia M, Stahl M, von Weyhern C, Weirich G, Pühringer-Oppermann F (2006) The prognostic significance of genetic polymorphisms (methylenetetrahydrofolate reductase C677T, methionine synthase A2756G, thymidilate synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma. Br J Cancer 94: 203-207
23. Schneider S, Uchida K, Salonga D, Yochim J M, Danenberg KD, Danenberg PV (2004) Quantitative determination of p16 gene expression by RT-PCR. Methods Mol Biol 281: 91-103
24. Schoffski P (2002) New drugs for treatment of gastric cancer. Ann Oncol 13(s4): 13-22
25. Schwartz G, Johnson TR, Goetz A, Burris H, Smetzer L, Lampkin T, Sailstad J, Hohneker JA, Von Hoff DD, Rowinsky EK (2001) A phase I pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies. Clin Cancer Res 7(7): 1901-1911
26. Simon R (1989) Optimal two-stage design for phase II clinical trials. Controlled Clin Trials 10: 1-10
27. Skibola CF, Smith MT, Kane E, Roman E, Rollinson S, Cartwright RA, Morgan G (1999) Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci 96: 12810-12815
28. Smith GK, Bigley JW, Dev IK, Duch DS, Ferone R, Pendergast W (1999) GW1843: A potent, noncompetitive thymidylate synthase inhibitor - preclinical and preliminary clinical studies. In Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy, Jackman AL (ed). pp 203-227. Totowa, NJ: Humana Press, Inc
29. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christina MC, Gwyther SC (2000) New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 92(3): 205-216
30. Thomas A, Pluzanska A, Daniel F, Marples M, Falk S, Miller RM, Evans EF (2005) A phase I/II study of plevitrexed with nutritional vitamin supplementation in gastric cancer. Proc Am Soc Clin Onc 23(16S): (abstract 4231)
31. Tsujitani S, Konishi K, Suzuki K, Oka S, Gomyo Y, Matsumoto S, Hirooka Y, Kaibara N (2000) Expression of thymidylate synthase in relation to survival and chemosensitivity in gastric cancer patients. J Exp Clin cancer Res 19: 189-195
32. Vanhoefer U, Rougier P, Wilke HJ, Ducreux P, Lacave AJ, Van Cutsem E, Planker M, Dos Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA (2000) Final results of randomised phase II trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin vs etoposide, leucovorin, and fluorouracil vs infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer and Cooperative Group. J Clin Oncol 18(14): 2648-2657
33. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil vs fluorouracil, doxorubicin, and methotrexate in advanced eosphagogastric cancer. J Clin Oncol 15(1): 261-267
34. Winski S, Srebernak M, Brown EN, Tomkinson B, Emerson D (2004) In vivo efficacy of the novel thymidylate synthase inhibitor, OSI-7904L, in combination with cisplatin or oxaliplatin in xenograft models. Proc AACR 45: A5381